vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $188.3M, roughly 1.9× BRC Group Holdings, Inc.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs 8.6%, a 39.4% gap on every dollar of revenue. On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs -21.9%). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs -15.4%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
LIVN vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $188.3M |
| Net Profit | $30.9M | $90.3M |
| Gross Margin | 65.2% | 79.5% |
| Operating Margin | 11.8% | 32.3% |
| Net Margin | 8.6% | 47.9% |
| Revenue YoY | 12.1% | -21.9% |
| Net Profit YoY | -44.7% | 1710.8% |
| EPS (diluted) | $0.57 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | $188.3M | ||
| Q3 25 | $357.8M | $215.3M | ||
| Q2 25 | $352.5M | $188.2M | ||
| Q1 25 | $316.9M | $197.2M | ||
| Q4 24 | $321.8M | $241.0M | ||
| Q3 24 | $318.1M | $225.5M | ||
| Q2 24 | $318.6M | $256.0M | ||
| Q1 24 | $294.9M | $263.4M |
| Q4 25 | $30.9M | $90.3M | ||
| Q3 25 | $26.8M | $91.1M | ||
| Q2 25 | $27.2M | $139.5M | ||
| Q1 25 | $-327.3M | $-10.0M | ||
| Q4 24 | $55.9M | $-5.6M | ||
| Q3 24 | $33.0M | $-284.4M | ||
| Q2 24 | $16.3M | $-433.6M | ||
| Q1 24 | $-41.9M | $-49.2M |
| Q4 25 | 65.2% | 79.5% | ||
| Q3 25 | 68.4% | 83.7% | ||
| Q2 25 | 67.8% | 81.3% | ||
| Q1 25 | 69.7% | 81.4% | ||
| Q4 24 | 68.2% | 79.8% | ||
| Q3 24 | 70.8% | 82.1% | ||
| Q2 24 | 68.7% | 84.5% | ||
| Q1 24 | 70.3% | 85.3% |
| Q4 25 | 11.8% | 32.3% | ||
| Q3 25 | 15.1% | 30.4% | ||
| Q2 25 | 15.4% | 5.7% | ||
| Q1 25 | 15.3% | -31.2% | ||
| Q4 24 | 11.5% | -69.2% | ||
| Q3 24 | 11.2% | -36.4% | ||
| Q2 24 | 12.6% | -90.8% | ||
| Q1 24 | 5.5% | -6.1% |
| Q4 25 | 8.6% | 47.9% | ||
| Q3 25 | 7.5% | 42.3% | ||
| Q2 25 | 7.7% | 74.1% | ||
| Q1 25 | -103.3% | -5.1% | ||
| Q4 24 | 17.4% | -2.3% | ||
| Q3 24 | 10.4% | -126.1% | ||
| Q2 24 | 5.1% | -169.4% | ||
| Q1 24 | -14.2% | -18.7% |
| Q4 25 | $0.57 | $2.78 | ||
| Q3 25 | $0.49 | $2.91 | ||
| Q2 25 | $0.50 | $4.50 | ||
| Q1 25 | $-6.01 | $-0.39 | ||
| Q4 24 | $1.04 | $-0.01 | ||
| Q3 24 | $0.60 | $-9.39 | ||
| Q2 24 | $0.30 | $-14.35 | ||
| Q1 24 | $-0.78 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $226.6M |
| Total DebtLower is stronger | $376.1M | $1.4B |
| Stockholders' EquityBook value | $1.2B | $-171.5M |
| Total Assets | $2.6B | $1.7B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | $226.6M | ||
| Q3 25 | $646.1M | $184.2M | ||
| Q2 25 | $593.6M | $267.4M | ||
| Q1 25 | $738.4M | $138.3M | ||
| Q4 24 | $428.9M | $146.9M | ||
| Q3 24 | $346.4M | $159.2M | ||
| Q2 24 | $329.2M | $236.9M | ||
| Q1 24 | $309.2M | $190.7M |
| Q4 25 | $376.1M | $1.4B | ||
| Q3 25 | $434.5M | $1.3B | ||
| Q2 25 | $430.6M | $1.3B | ||
| Q1 25 | $628.2M | $1.4B | ||
| Q4 24 | $627.0M | $1.5B | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | $-171.5M | ||
| Q3 25 | $1.2B | $-260.5M | ||
| Q2 25 | $1.1B | $-351.7M | ||
| Q1 25 | $1.0B | $-496.8M | ||
| Q4 24 | $1.3B | $-488.2M | ||
| Q3 24 | $1.3B | $-497.6M | ||
| Q2 24 | $1.2B | $-218.3M | ||
| Q1 24 | $1.2B | $228.4M |
| Q4 25 | $2.6B | $1.7B | ||
| Q3 25 | $2.6B | $1.7B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.6B | $1.5B | ||
| Q4 24 | $2.5B | $1.8B | ||
| Q3 24 | $2.5B | $2.2B | ||
| Q2 24 | $2.5B | $3.2B | ||
| Q1 24 | $2.5B | $5.0B |
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $26.2M |
| Free Cash FlowOCF − Capex | $50.2M | — |
| FCF MarginFCF / Revenue | 13.9% | — |
| Capex IntensityCapex / Revenue | 8.9% | — |
| Cash ConversionOCF / Net Profit | 2.67× | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $26.2M | ||
| Q3 25 | $85.1M | $-60.6M | ||
| Q2 25 | $62.9M | $-25.6M | ||
| Q1 25 | $24.0M | $184.0K | ||
| Q4 24 | $78.7M | $-2.7M | ||
| Q3 24 | $51.0M | $19.5M | ||
| Q2 24 | $43.4M | $111.5M | ||
| Q1 24 | $10.0M | $135.4M |
| Q4 25 | $50.2M | — | ||
| Q3 25 | $62.2M | — | ||
| Q2 25 | $47.8M | — | ||
| Q1 25 | $13.2M | — | ||
| Q4 24 | $68.3M | — | ||
| Q3 24 | $32.8M | — | ||
| Q2 24 | $31.2M | — | ||
| Q1 24 | $3.6M | — |
| Q4 25 | 13.9% | — | ||
| Q3 25 | 17.4% | — | ||
| Q2 25 | 13.6% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 21.2% | — | ||
| Q3 24 | 10.3% | — | ||
| Q2 24 | 9.8% | — | ||
| Q1 24 | 1.2% | — |
| Q4 25 | 8.9% | — | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 3.4% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 5.7% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 2.2% | — |
| Q4 25 | 2.67× | 0.29× | ||
| Q3 25 | 3.18× | -0.66× | ||
| Q2 25 | 2.32× | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 2.65× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
